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domains. Problems with physical component of QoL increased
with BMI increase, while for “pain/discomfort” and
“anxiety/depression”, normal weight and severe obese people
complained more than overweight and obese people. CON-
CLUSIONS: obesity is expensive for the health care system and
society and compromises individuals’ QoL. Policy makers should
pay attention to identiﬁcation, promotion and implementation
of programs aimed at preventing obesity.
OSTEOPOROSIS
OSTEOPOROSIS—Cost Studies
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OBJECTIVE: Hip fracture rates in Taiwan have been reported
to be higher than other Asian countries. The objective of this
analysis was to assess the cost-effectiveness of risedronate 
compared to alendronate in high-risk osteoporotic patients in
Taiwan. METHODS: A fracture-incidence based Markov model
of osteoporosis, where patients transition across states, was used
to estimate cost per fracture averted and cost per QALY gained.
The population included 1000 women aged 65 years with low
bone density and previous vertebral fracture, treated over a life-
time with either risedronate or alendronate. Model inputs spe-
ciﬁc to Taiwan included general population hip fracture rates,
mortality rates, health utilities, and relative risk reduction of
fracture with therapy (from published studies). The launch price
of risedronate was anticipated as 20% higher than alendronate
(risedronate: 16,394NT$/year; risedronate 13,662NT$/year).
Vertebral fracture rates were not available for Taiwan, thus inci-
dence rates were based on US ratios of hip to vertebral fracture.
The cost of fracture was included only for ﬁrst year after frac-
ture since chronic treatment is not routine in Taiwan. RESULTS:
There were 58 fewer hip fractures, 35 fewer vertebral fractures
and 52 more QALYs with risedronate compared to alendronate.
The fracture costs were 15% lower for patients treated with rise-
dronate, however total costs (including drug costs) were higher
(259,358NT$ [risedronate] vs. 227,296NT$ [alendronate]). The
incremental cost was 343,225NT$ (8400€) per any fracture
averted, 552,787NT$ (13,500€) per hip fracture averted, and
617,934NT$ (15.100€) per QALY gained for risedronate com-
pared to alendronate. CONCLUSIONS: Risedronate treatment
for high-risk osteoporotic women may represent a cost-effective
strategy for improving care of patients in Taiwan, despite the fact
that there are fewer downstream costs for treatment of chronic
fracture-related disability.
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OBJECTIVE: Osteoporosis and its related fractures are a major
source of illness and costs. Approximately 2 million post-
menopausal women have osteoporosis in France, resulting in an
annual cost of 1€ billion. This study assessed the clinical and eco-
nomic impact of risedronate therapy in a population of women
with post-menopausal osteoporosis (PMO) using a computer
simulation model. METHODS: A fracture incidence based
Markov model of osteoporosis, where patients transition across
outcome states over time, was used to estimate the incremental
cost per fracture prevented and the cost per QALY gained. The
analysis was conducted for a cohort of women aged 70 years
with low bone mineral density and prevalent vertebral fracture.
The impact of risedronate was assessed over 10 years, with
patients treated for the ﬁrst 5 years. Analyses used French epi-
demiological and cost data (from published literature). Relative
risk reductions with risedronate were set at 60% for hip fracture
and 41% for vertebral fracture. RESULTS: When added costs
are expressed per unit of beneﬁt gained, the results were approx-
imately 15,861€ per hip fracture prevented and 4351€ per 
QALY gained. Without treatment, 760 radiographic vertebral
fractures and 104 hip fractures occurred in a cohort of 1000
patients. Treatment with risedronate reduced the fractures occur-
ring during the treatment period, resulting in a smaller number
of fractures over 10 years: 604 vertebral fractures and 77 hip
fractures. If the analysis were extended to the entire PMO 
population in France, treatment with risedronate could result 
in a reduction of 312,000 vertebral fractures and 54,000 hip
fractures over 10 years. CONCLUSIONS: Analysis on a popu-
lation level demonstrates the magnitude of fractures and the cost
savings that could be averted among French women. Using
country-speciﬁc data, simulation models can provide realistic
estimates of the impact of disease and treatment costs in a 
population.
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OBJECTIVES: This study assesses disease burden and treatment
costs in patients with Paget’s Disease (PD) compared with a
matched comparator group (MC). METHODS: This is an obser-
vational study using 2001–2002 MarketScan Research databases
(MEDSTAT, Ann Arbor, MI), which consist of medical claims,
prescriptions and encounter data on 2 million active and retired
USA employees. Details include age, gender, drugs prescribed,
medical services rendered, ICD-9 diagnostic codes and costs. We
linked annual ﬁles to create a longitudinal panel with 24 months
of observation. Persons with PD were identiﬁed by ICD-9 code
731.0. A MC was selected using gender, age and risk adjustment
score, which was derived from a DCG/HCC classiﬁcation system
based on presence of 189 medical conditions. In this analysis, we
calculated the prevalence of 30 conditions linked to PD and total
costs for all medical care. The prevalence of co-morbidities and
health care costs were compared in PD and MC, and differences
tested using chi-square and t-tests, as appropriate. RESULTS:
Our study identiﬁed 488 individuals, 244 with PD and 244
matched comparators (MC). The average age was 72.7 years;
50.8% were female. Largest differences in co-morbidities
detected between PD patients and MC were: pathological frac-
tures (4.9% vs. 0.4%), heart murmurs (3.3% vs. 0.4%), frac-
tures of femur other than neck (2.9% vs. 0.4), spinal stenosis
(2.5% vs. 0.4%), hypercalcemia (1.6% vs. 0.4%), and bone neo-
plasms (7.8% vs. 2.5%), respectively. Annual per patient outpa-
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tient costs were signiﬁcantly higher in PD patients (PD $10,687
vs. MC $8,083 (p < 0.05)), especially associated with compres-
sion fractures, heart murmurs, and spinal stenosis. Inpatient
costs (PD $7045 vs. MC $7514), and prescription costs (PD
$5312 vs. MC $4844) were comparable. CONCLUSIONS: This
study is the ﬁrst to link higher treatment costs with increased
prevalence of co-morbidities associated with PD.
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OBJECTIVES: The cost of treating fractures has a signiﬁcant
impact on Medicare expenditures, totalling in the billions of
dollars annually. The expected cost of treatment for electrical
and ultrasound bone stimulators in the concomitant conserva-
tive treatment of stable nonunion fractures was assessed to iden-
tify the least costly stimulator. METHODS: Treatment pathways
for ﬁve different bone stimulators—Exogen®, Physio-Stim®Lite,
OL1000 Bone Growth Stimulator, OrthoPak®, and EBI Bone
Healing System®—were modelled using a decision tree (TreeAge
Data v3.0.13). Treatment failures were assumed to require
surgery. Probabilities of treatment success came from published
literature, manufacturers’ data, and patient registry data. Cost
data came from published literature and Durable Medical 
Equipment Regional Carriers (DMERCs). For each stimulator,
the expected cost of treating a nonunion fracture was calculated
by folding back the decision tree. One-way sensitivity analyses
were performed by varying all probabilities by ±0.20 and all
costs by ±50%. A Monte Carlo simulation was conducted to
determine the optimal bone stimulator for a hypothetical cohort
of 10,000 patients. The analysis was undertaken from the per-
spective of United States Centers for Medicare and Medicaid Ser-
vices. RESULTS: Exogen® had the lowest expected cost ($6610), 
followed by Physio-Stim®Lite ($8714). Sensitivity analyses
demonstrated expected costs were sensitive to the probability of
success: Exogen® would have the lowest expected cost if its
probability of success were at least 0.745, while OL1000 would
have the lowest expected cost if its probability of success were
at least 0.84. The Monte Carlo simulation showed that Exogen®
was the optimal stimulator for 85% of patients, Physio-
Stim®Lite for 14%, and EBI Bone Healing System® for 1%.
CONCLUSIONS: Exogen® was the least costly bone stimulator
for conservatively treated nonunion fractures. Public insurers
should consider the cost beneﬁts of expanding coverage for
Exogen® to include concomitant conservative treatment of
stable non-union fractures.
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OBJECTIVES: To assess the medical management and cost of
rachialgia in untreated osteoporotic postmenopausal women 
and identify the cost induced by vertebral fracture. METHODS:
EMERAUDE was a multicenter, prospective, observational study
over 6 months. A total of 113 rheumatologists enrolled 427 non-
treated osteoporotic patients between 65 and 85 years-old suf-
fering from thoracic and/or lumbar rachialgia. A DEXA Bone
Mineral Density measurement and spine x-rays were performed
at the beginning of the study. A central reading of x-rays 
differentiated patients with or without vertebral fracture. 
Clinical data, medical consumptions and management care 
were recorded. RESULTS: We report results about the ﬁrst 195
patients followed during three months. The mean age of patients
was 74 years. A total of 50.3% of patients had a vertebral frac-
ture. Patients with vertebral fracture were older (75.5 years
versus 72.6 years; p = 0.0003) and had a major height loss than
women without vertebral fracture. Rachialgia intensity assessed
by a visual analogical scale (0–100) was higher for women with
vertebral fracture (64.8 versus 59.9; p = 0.008). 46% of women
with vertebral fracture had had a history of a non-traumatic
peripheral fracture against 32% for women without vertebral
fracture (p = 0.045). For the 3 months before inclusion; the mean
medical cost was 1207€ for patient with vertebral fracture (70%
due to hospitalisations) against only 425€ for non-fracture
woman. During the three months after inclusion, the mean cost
of woman with vertebral fracture was 903€, nearly 3 times
higher than the management cost of a non-fracture woman (p =
0.024). CONCLUSION: Our results show that the cost of
women suffering from rachialgia depends on the aetiology.
Rachialgia secondary to a vertebral fracture induce a higher
medical consumption than rachialgia without spinal fracture.
These preliminary results, that need to be conﬁrmed, suggest that
vertebral fracture, with no routine corrective treatment, is 
nevertheless a costly condition.
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OBJECTIVES: Miacalcic was shown to be effective in reducing
pain in patients with osteoporotic vertebral fracture (level od rec-
ommendation A). We performed cost-effective analysis of mia-
calcic in comparison to standard therapy with non-steroid
anti-inﬂammatory drugs or analgetics in patients with osteo-
porotic vertebral fracture accompanied with back pain.
METHODS: Subjects included 28 outpatient postmenopausal
women with history of 1 to 5 vertebral fractures who presented
with back pain. 14pts were treated with miacalcic and 14—with
standard therapy. The length of miacalcic treatment was 2 weeks,
the length of follow-up was 3 months. Visual analog scale was
used to assess pain and QUALEFFO-41 to measure quality of
life. The direct and indirect costs of treatment were calculated.
At the start the main clinical characteristics were similar in both
groups. RESULTS: Miacalcic group showed shorter period of
acute pain (7.6 days vs 15.8 days), lower VAS at 2nd week, better
quality of life according to QUALEFFO-41, more patients free
of pain (63% vs 32%), P < 0.05. Although direct costs were
higher in miacalcic (4452 vs 847 rouble), indirect costs were
lower than in controls (1325 vs 4421 rouble). CONCLUSIONS:
Miacalcic is cost-effective in treatment of pain in vertebral frac-
ture osteoporotic patients.
